42 results on '"WISWELL, DEREK"'
Search Results
2. Supplementary Table 6 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
3. Supplementary Figure 7 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
4. Supplementary Table 3 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
5. Supplementary Figure 1 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
6. Supplementary Figure 9 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
7. Supplementary Figure 2 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
8. Supplementary Figure 4 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
9. Supplementary Figure 3 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
10. Supplementary Table 8 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
11. Supplementary Figure 5 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
12. Supplementary Table 7 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
13. Supplementary Table 4 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
14. Supplementary Figure 6 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
15. Supplementary Table 2 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
16. Supplementary Table 5 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
17. Supplementary Figure 8 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
18. Supplementary Figure Legends from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
19. Supplementary Table 1 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
20. Data from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
21. Data Supplement from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
22. Supplementary Table 2 from Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
23. Data from Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
24. Supplementary Table 1 from Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
25. Comprehensive Analysis of the Therapeutic IgG4 Antibody Pembrolizumab: Hinge Modification Blocks Half Molecule Exchange In Vitro and In Vivo
26. Development of a novel capillary electrophoresis-based approach for detection of anti-drug antibody responses
27. Integrin [alpha]4[beta]1 function is required for cell survival in developing retina
28. Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene
29. Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors
30. Abstract 4521: Evaluation of the relationship between serum exposure, receptor (GITR) availability and tumor suppression following administration of the anti-GITR antibody DX400 in mouse syngeneic tumor models
31. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach—Part 1
32. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach—Part 2
33. Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors
34. Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
35. ChemInform Abstract: Design, Synthesis and SAR of Thienopyridines as Potent CHK1 Inhibitors.
36. Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
37. Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases
38. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors
39. Pyrazolo[1,5- a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2
40. Integrin α4β1 function is required for cell survival in developing retina
41. Comprehensive Analysis of the Therapeutic IgG4 Antibody Pembrolizumab: Hinge Modification Blocks Half Molecule Exchange In Vitro and In Vivo.
42. The Role of Anti-Drug Antibodies in the Pharmacokinetics, Disposition, Target Engagement, and Efficacy of a GITR Agonist Monoclonal Antibody in Mice.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.